Pharmaron Beijing Revenue vs. Current Valuation
| 300759 Stock | 27.51 0.52 1.93% |
Total Revenue | First Reported 2019-03-31 | Previous Quarter 2.7 B | Current Value 2.9 B | Quarterly Volatility 794.5 M |
For Pharmaron Beijing profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharmaron Beijing to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharmaron Beijing Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharmaron Beijing's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharmaron Beijing Co over time as well as its relative position and ranking within its peers.
Pharmaron |
Pharmaron Beijing Current Valuation vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pharmaron Beijing's current stock value. Our valuation model uses many indicators to compare Pharmaron Beijing value to that of its competitors to determine the firm's financial worth. Pharmaron Beijing Co is the top company in revenue category among its peers. It also is the top company in current valuation category among its peers reporting about 4.15 of Current Valuation per Revenue. At present, Pharmaron Beijing's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharmaron Beijing by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharmaron Beijing's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Pharmaron Revenue vs. Competition
Pharmaron Beijing Co is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 130.53 Billion. Pharmaron Beijing holds roughly 11.54 Billion in revenue claiming about 9% of equities under Health Care industry.
Pharmaron Current Valuation vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Pharmaron Beijing |
| = | 11.54 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Pharmaron Beijing |
| = | 47.86 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Pharmaron Current Valuation vs Competition
Pharmaron Beijing Co is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 137.2 Billion. Pharmaron Beijing totals roughly 47.86 Billion in current valuation claiming about 35% of equities under Health Care industry.
Pharmaron Beijing Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pharmaron Beijing, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharmaron Beijing will eventually generate negative long term returns. The profitability progress is the general direction of Pharmaron Beijing's change in net profit over the period of time. It can combine multiple indicators of Pharmaron Beijing, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -152.3 M | -144.6 M | |
| Interest Income | 33.5 M | 30.2 M | |
| Operating Income | 1.8 B | 1.1 B | |
| Net Income From Continuing Ops | 1.6 B | 959 M | |
| Income Before Tax | 1.8 B | 1.1 B | |
| Net Income Applicable To Common Shares | 1.9 B | 2 B | |
| Net Income | 1.6 B | 975.9 M | |
| Income Tax Expense | 334.6 M | 351.3 M | |
| Change To Netincome | -340.4 M | -323.4 M |
Pharmaron Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pharmaron Beijing. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharmaron Beijing position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharmaron Beijing's important profitability drivers and their relationship over time.
Use Pharmaron Beijing in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharmaron Beijing position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharmaron Beijing will appreciate offsetting losses from the drop in the long position's value.Pharmaron Beijing Pair Trading
Pharmaron Beijing Co Pair Trading Analysis
The ability to find closely correlated positions to Pharmaron Beijing could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharmaron Beijing when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharmaron Beijing - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharmaron Beijing Co to buy it.
The correlation of Pharmaron Beijing is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharmaron Beijing moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharmaron Beijing moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharmaron Beijing can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pharmaron Beijing position
In addition to having Pharmaron Beijing in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Baby Boomer Prospects Thematic Idea Now
Baby Boomer Prospects
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 99 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Pharmaron Stock
To fully project Pharmaron Beijing's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pharmaron Beijing at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pharmaron Beijing's income statement, its balance sheet, and the statement of cash flows.